Abion announced on the 16th that it will participate as a poster presentation company at the 'ATS (American Thoracic Society) 2024,' the largest thoracic society in the United States. The company will present the non-clinical efficacy evaluation results of its viral respiratory disease inhalation treatment 'ABN101.'
ATS is attended by the largest number of respiratory specialists in the United States and is a venue for presenting the latest clinical research results on respiratory treatments and diseases. This year, it will be held in San Diego, USA, from the 17th to the 22nd.
'ABN101' is a next-generation interferon beta. It improves the material stability of the existing natural interferon beta and increases production yield by more than 500 times, enabling research and production of various formulations at an economical cost. It was also developed as a dry powder formulation, confirming that its biological activity increased more than threefold compared to the natural form.
The company is developing 'ABN101' as a broad-spectrum antiviral drug. Through in vitro non-clinical experiments, 'ABN101' has been verified for preventive and therapeutic effects against coronavirus (SARS-CoV-2) and its variants, influenza virus, and respiratory syncytial virus (RSV).
Abion has formulated the next-generation interferon beta 'ABN101' into a dry powder inhaler (DPI) optimized for treating respiratory viral infections. Last year at ATS, the company administered it to a monkey animal model and monitored blood and bronchoalveolar lavage fluid, presenting excellent pharmacokinetic results.
The company stated, "At this year's ATS, we will present the excellent therapeutic and preventive effects against coronavirus and influenza virus studied by administering ABN101 dry powder to the respiratory tract of large animals."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
